News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
HER2-negative breast cancers show 17q12 deletion and ERBB2 loss
canceronco.com
Jan 19, 2025, 22:15

HER2-negative breast cancers show 17q12 deletion and ERBB2 loss

A recent paper by X. Qiu et al. was mentioned by Elisabetta Bonzano, Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, on X:

“Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2”

Authors: X. Qiu et al.

HER2-negative breast cancers show 17q12 deletion and ERBB2 loss

“Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2.

  • ERBB2 mRNA levels are associated with significant variations in mutational landscapes and transcriptional profiles.
  • 17q12del with heterozygous loss of ERBB2 is a biologically distinct subgroup of BCs with very low HER2 expression levels.
  • Metastatic BCs with a 17q12del with heterozygous loss of ERBB2 have worse OS.”

More posts featuring Elisabetta Bonzano.

Breast Cancer cancer Elisabetta Bonzano OncoDaily Oncology
Special Coverage
Insight
Jan 20, 2025, 04:14
Laura Bukavina discusses a paper on BCG treatment for patients with urothelial carcinoma of the prostatic urethra
Insight
Jan 20, 2025, 04:00
FDA approved datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer
Career
Jan 20, 2025, 03:10
Lawrence “Larry” Deist Appointed to Board of Directors at Rally Foundation for Childhood Cancer Research
Blog
Jan 20, 2025, 02:54
Drew Moghanaki: A new medical oncology position at the VA Medical Center in Long Beach
Science
Jan 20, 2025, 02:44
Assessment of fitness for bleomycin use and management of bleomycin pulmonary toxicity in patients with classical HL
Science
Jan 20, 2025, 02:16
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer
Blog
Jan 20, 2025, 02:14
Akriti Jain: Grateful to present at Cleveland Clinic ASH review
Career
Jan 19, 2025, 23:12
Kimryn Rathmell Steps Down as NCI Director, Concluding a Pivotal Leadership Era
Blog
Jan 19, 2025, 23:07
Antonio D'Alessio: Our work on neoadjuvant ICI in HCC has been chosen for the 2025 ASCO GI Merit Award
Science
Jan 19, 2025, 22:56
Bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab in pleural mesothelioma
Insight
Jan 19, 2025, 22:15
HER2-negative breast cancers show 17q12 deletion and ERBB2 loss
Insight
Jan 19, 2025, 22:11
Nico Gagelmann: Ide-cel versus cilta-cel for relapsed or refractory multiple myeloma